Journal of Diabetes and Endocrinology
Subscribe to JDE
Full Name*
Email Address*

Article Number - B1452FE4454

Vol.4(4), pp. 51-54 , September 2013
ISSN: 2141-2685

 Total Views: 0
 Downloaded: 0

Full Length Research Paper

Comparison between the clinical efficacy of linagliptin and sitagliptin

Naoto Kamatani1*, Taiya Katoh1, Yoshikuni Sawai1, Hitoshi Kanayama1, Naoyuki Katada1 and Mitsuyasu Itoh2

1Department of Internal Medicine, Toyota Kosei Hospital, JA Aichi Koseiren Toyota, Aichi, 470-0396, Japan.

2Department of Endocrinology, Metabolism and Internal Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan.

Email: [email protected]

 Accepted: 28 August 2013  Published: 30 September 2013

Copyright © 2013 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0

After the introduction of dipeptidylpeptidase-4 (DPP-4) inhibitors into the treatment for diabetes, these drugs have been widely used because of their capability and safety. Therefore, the clinical efficacy of linagliptin to sitagliptin was compared. Patients with type 2 diabetes, in whom pharmacological treatment was recently started, were randomly assigned to two separate groups, namely sitagliptin (50 mg/day) group and linagliptin (5 mg/day) group. A total of 42 patients (21 patients in each group), who received a single dose of their respective pharmacological agents, were evaluated in this study. The study primarily focused on changes in HbA1c levels before and 24 weeks after drug administration and effects of these drugs on renal function, liver function, and fat. Significant improvement in HbA1c levels (%) was found in both linagliptin and sitagliptin groups. Significant improvements were observed in low density lipoprotein-cholesterol (LDL-C) levels in patients in the linagliptin group. Linagliptin offers a great potential in terms of improving effect on blood glucose and lipid profile. This study has demonstrated that linagliptin can be a valuable option in the treatment of patients with type 2 diabetes.


Key words: Linagliptin, dipeptidylpeptidase-4 (DPP-4) inhibitors, type 2 diabetes, glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C).

David BS (2012). Measurement of hemoglobin A(1c): A new twist on the path to harmony. Diabetes Care 35(12):2674-2680.
PMid:23173136 PMCid:PMC3507560
Drucker DJ, Nauck MA (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696-1705.
Groop P, Cooper M, Perkovic V, Emser A, Von Eynatten M, Woerle H (2012). Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment for Diabetic Nephropathy. Poster No. 953-P. Presented at the American Diabetes Association® (ADA) 72nd Scientific Sessions. June 8-12, Philadelphia, PA.
Gross JL, Rogers J, Polhamus D, Gillespie W, Friedrich C, Gong Y, Monz BU, Patel S, Staab A, Retlich S (2013). A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. BMJ. 3(3):e001844.
Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA (2010). Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51(5):1584-1592.
PMid:20225248 PMCid:PMC2862093
Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA (2009). Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes. Metab. 11(8):786-794.
Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi SI (2013). Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 12(1):125.
PMid:23984879 PMCid:PMC3765742
Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, Kossmann S, Gori T, Wenzel P, Schulz E, Grabbe S, Klein T, Münzel T, Daiber A (2012). Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc. Res. 96(1):140-149.
Ono M, Oe K, Saibara T (2011). Attenuation of fatty accumulation in hepatocyte by incretin--expectation of novel medicine for treatment of NASH. Nihon Rinsho. 69(5):853-858.
Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008). (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-Quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325(1):175-182.


APA (2013). Comparison between the clinical efficacy of linagliptin and sitagliptin. Journal of Diabetes and Endocrinology, 4(4), 51-54.
Chicago Naoto Kamatani, Taiya Katoh, Yoshikuni Sawai, Hitoshi Kanayama, Naoyuki Katada and Mitsuyasu Itoh. "Comparison between the clinical efficacy of linagliptin and sitagliptin." Journal of Diabetes and Endocrinology 4, no. 4 (2013): 51-54.
MLA Naoto Kamatani, et al. "Comparison between the clinical efficacy of linagliptin and sitagliptin." Journal of Diabetes and Endocrinology 4.4 (2013): 51-54.

Subscription Form